Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692448 | 0.89 | NLRP3 (0.40) | NLRP3LMNACA12CA1CA2 | |
| SCHEMBL20692044 | 0.88 | LMNA (0.41) | NLRP3LMNAMEN1KMT2ACA12 | |
| SCHEMBL20692394 | 0.83 | NLRP3 (0.41) | NLRP3MEN1KMT2ACA12CA1 | |
| SCHEMBL20692039 | 0.83 | NLRP3 (0.41) | NLRP3MEN1KMT2ACA12CA1 | |
| SCHEMBL23481750 | 0.83 | NLRP3 (0.41) | NLRP3MEN1KMT2ACA12CA1 | |
| SCHEMBL25033411 | 0.82 | NLRP3 (0.30) | NLRP3 | |
| SCHEMBL23481828 | 0.82 | NLRP3 (0.37) | NLRP3LMNAMEN1KMT2A | |
| SCHEMBL20692040 | 0.82 | NLRP3 (0.37) | NLRP3LMNAMEN1KMT2A | |
| SCHEMBL20692041 | 0.82 | NLRP3 (0.37) | NLRP3LMNAMEN1KMT2A | |
| SCHEMBL21892935 | 0.81 | NLRP3 (0.53) | NLRP3CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885LMNA 1759/4885NMT1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.